|
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Personnel/Miscellaneous
Corporate News Bad Neustadt / Saale | 11th August 2020
Supervisory Board of RHÖN-KLINIKUM AG Appoints Two New Members to Board of Management - Management Board of RHÖN-KLINIKUM AG extended by two members in the course of strategic partnership with Asklepios Kliniken GmbH & Co. KGaA - Supervisory Board appoints Dr. Christian Höftberger as of 15th August 2020 and Dr. Stefan Stranz as of 1st September 2020 to Board of Management - Extending Board of Management sets course for consistent implementation of the common goal of a holistic healthcare provider with a sustainable strategy for the future
The Supervisory Board of RHÖN-KLINIKUM AG appointed two new members to the Board of Management on 10th August and thus took an important step in setting the course for the strategic partnership. Together with parent company Asklepios RHÖN-KLINIKUM AG wishes to drive its concepts for innovative healthcare forwards with a good portion of positive energy and pioneer new routes in cutting-edge medical care in Germany. The university hospitals in Giessen and Marburg (UKGM) - together the third largest university hospital in Germany - will play a key role here. Already today with its five sites providing maximum and intermediate medical care RHÖN-KLINIKUM AG stands for excellent medical care with a direct link to the two university hospitals with their research institutes. This strength also needs to be exploited in the future for the benefit of our patients and employees. The Supervisory Board also decided at the meeting that no new Chairman or Spokesman of the Management Board should be appointed initially. Eugen Münch, Chairman of the Supervisory Board of RHÖN-KLINIKUM AG, stated: "With Dr. Christian Höftberger and Dr. Stefan Stranz the Supervisory Board has appointed to the Board of Management of RHÖN-KLINIKUM AG two strong personalities who both have many years of talented management experience in the German healthcare system. The appointments are an important basis for the strategic cooperation between the two companies, in order to achieve more than the addition of skills from two solitaires to create a group that stands for excellent medical care - locally, regionally and for the German hospital market as a whole." Dr. Höftberger who has a PhD in law has been the Regional Managing Director for Asklepios Kliniken GmbH & Co. KGaA in the German Federal State of Hesse since June 2017. Most recently he took on the Presidency of the Hospital Federation in Hesse (Hessische Krankenhausgesellschaft - HKG). He was already a member of the HKG Board of Management from 2010 to 2014. From 2014 to 2017 Dr. Höftberger worked for the Asklepios Group in Hamburg. Before that he was the Managing Director of Asklepios Klinik Lich GmbH where he successfully moved the company into a strategic position and completed its re-orientation, among other things, and also built up strong links with referring physicians for cooperative medical care. Before moving to Asklepios in 2012 to manage the site in Lich he worked for RHÖN-KLINIKUM AG where his last position was as the Commercial Director at the university hospital in Giessen. Dr. Höftberger studied law at the universities in Vienna and Salzburg. Dr. Christian Höftberger who will become a member of the Board of Management of RHÖN-KLINIKUM AG as of 15th August 2020 stated: "I am very much looking forward to my new position and being able to work alongside my fellow board members, Dr. Gunther Weiss, Prof. Bernd Griewing and Dr. Stefan Stranz. I am totally convinced that RHÖN will be able to take an important step under the roof of Asklepios and ensure the long-term future of the company which will benefit both patients and employees. RHÖN and Asklepios will strategically complement each other and be strong together in the future. Savings which are made from economies of scale will be used to create new jobs and make investments in modern patient care." Dr. Stefan Stranz has a degree in macroeconomics and a PhD in medicine and has been the Managing Director of Asklepios Kliniken Hamburg GmbH since November 2019. Before that he worked for Schön-Kliniken where he was the Managing Director who was responsible for North Germany and before that Dr. Stranz was the Managing Director of HELIOS Klinikum Erfurt GmbH. He has been working in the hospital industry for a total of more than 15 years already. Dr. Stranz's appointment to the RHÖN Board of Management is subject to the Supervisory Board of Asklepios Kliniken Hamburg GmbH consenting to his premature departure. Dr. Stefan Stranz stated: "With RHÖN and Asklepios two great names with a single mission are joining forces. Together we shall develop future-oriented concepts for healthcare and drive them forwards with a good portion of positive energy so that we can continue to offer excellent medical care long into the future. Under the same roof we have the best preconditions for modernising the German hospital market and making the best possible use of the corporate group economies of scale in each and every individual hospital." ----------------------------------------------------- RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. The hospital group offers excellent medical care with a direct link to universities and research institutes. Over 860,000 patients are treated every year at the five group hospitals located in Bad Berka, Bad Neustadt, Frankfurt (Oder), Giessen and Marburg where more than 18,000 employees work. RHÖN-KLINIKUM AG is currently exploiting the opportunities available to develop new areas of growth. Entering the forward-looking telemedicine market with Medgate Deutschland, the innovative RHÖN campus concept for offering future-orientated healthcare across sectoral boundaries in rural areas as well as consistently extending our gradual corporate digitalisation are key pillars of the corporate strategy.
Follow us: www.twitter.com/rhoenklinikumag www.xing.com/companies/rhön-klinikumag www.youtube.com/rhönklinikumag Contact Persons: RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt / Saale, Germany
11.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a.d.Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1115091 |
| End of News | DGAP News Service |
|
|
1115091 11.08.2020
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
